The 6 Wall Street analysts covering Seaport Therapeutics, Inc. hold a median 12-month price target of $35 — +69.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Seaport Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (44): Smaller than most of the companies we track.
Volatility (3): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own Seaport Therapeutics, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on SPTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +69.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 July 2026 | HC Wainwright & Co. | Initiates | Buy | $50 |
| 26 May 2026 | Citigroup | Initiates | Buy | $35 |
| 26 May 2026 | Citigroup | Initiates | Buy | — |
| 26 May 2026 | JP Morgan | Initiates | Overweight | $42 |
| 26 May 2026 | JP Morgan | Initiates | Overweight | — |
| 26 May 2026 | Leerink Partners | Initiates | Outperform | $35 |
| 26 May 2026 | Leerink Partners | Initiates | Outperform | — |
| 26 May 2026 | Stifel | Initiates | Buy | — |
| 26 May 2026 | Stifel | Initiates | Buy | $30 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 93% of US stocks
Cheaper than 97% of US stocks
Cheaper than 86% of US stocks
Higher than 35% of US stocks
Higher than 30% of US stocks
Higher than 95% of US stocks
Higher than 14% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SPTX appears on the weeks it earns a place.
Seaport Therapeutics reported its second quarter 2026 financial results and highlighted recent corporate and clinical progress in a Business Wire announcement from Boston.
Why it matters — SPTX watchers would care because the release provides an update on the company's financial performance and recent clinical and corporate developments.
The 6 Wall Street analysts covering Seaport Therapeutics, Inc. have a median 12-month price target of $35, with estimates ranging from $30 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering Seaport Therapeutics, Inc., 5 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Seaport Therapeutics, Inc. 1 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Seaport Therapeutics, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (44 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +69.5% from the last close, and Ticker Nerd's factor model ranks Seaport Therapeutics, Inc. 1 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Seaport Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SPTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $50 over the next 12 months.
Seaport Therapeutics, Inc. is a clinical-stage biotechnology company focused on inventing and developing novel oral medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders.
The most recent item we track (Business Wire, 3 Aug 2026): "Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress". Seaport Therapeutics reported its second quarter 2026 financial results and highlighted recent corporate and clinical progress in a Business Wire announcement from Boston.
Seaport Therapeutics, Inc. is a clinical-stage biotechnology company focused on inventing and developing novel oral medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company employs its proprietary Glyph platform to address limitations of clinically validated mechanisms, such as high first-pass metabolism, low bioavailability, and side effects, enabling innovative therapies with established efficacy and safety profiles. Seaport Therapeutics targets the neuropsychiatry sector within pharmaceuticals and biotech, aiming to deliver leading treatment options that improve patient outcomes. Its pipeline advances antidepressants and anxiolytics derived from these optimized mechanisms. With a team experienced in neuropsychiatry drug discovery and development, Seaport Therapeutics operates at the intersection of cutting-edge platform technology and targeted therapeutic innovation. Founded in 2024 and headquartered in Boston, Massachusetts, the company plays a role in advancing accessible oral treatments for serious mental health conditions in the competitive biopharmaceutical market.
CEO Ms. Daphne Zohar · 58 employees · United States · https://www.seaporttx.com